Skip to main content

Table 2 Pretreatment ADC values according to the molecular subtypes

From: Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study

 

Overall patient sample

Luminal A

Luminal B

HER2-enriched

Triple negative

ADC-values (10− 3 mm2/s, M ± SD

1.04 ± 0.24

1.05 ± 0.18

0.93 ± 0.21

1.07 ± 0.22

1.10 ± 0.29